Evidence map›Paper›PMID 37265750›Full record

ArticleBJR case reports2023

Imaging features of the renal lymphoma: case report and literature review.

Shaden Saleh Almousa, Ammar Ashraf, Ahmed Mohamed Abdelrahman, Mohamed Tahar Yacoubi

Open access · diamondAbstract readCase Reports
In one paragraph

Article in BJR case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Successful Treatment of Paraneoplastic Mesangioproliferative Glomerulonephritis in Mantle Cell Lymphoma Using Acalabrutinib and Rituximab.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shaden Saleh AlmousaDepartment of Medical Imaging, King Faisal University, Al-Ahsa, KSA, Saudi Arabia.
Ammar AshrafDepartment of Medical Imaging, King Abdulaziz National Guard Hospital, Al-Ahsa, KSA, Saudi Arabia.
Ahmed Mohamed AbdelrahmanDepartment of Medical Imaging, King Abdulaziz National Guard Hospital, Al-Ahsa, KSA, Saudi Arabia.
Mohamed Tahar YacoubiDepartment of Anatomical Pathology, King Abdulaziz National Guard Hospital, Al-Ahsa, KSA, Saudi Arabia.
King Abdulaziz Hospital · SAKing Faisal University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal affection is common in disseminated non-Hodgkin's lymphoma (NHL) which is known as secondary renal lymphoma (SRL). Primary renal lymphoma (PRL) is an exceedingly uncommon disease, which accounts for less than 1% of all renal masses. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL in both primary as well as secondary renal lymphomas. PRL is of paramount importance clinically as it is usually managed with neo-adjuvant chemotherapy followed by nephrectomy in contrast to the more frequently seen renal cell carcinoma, which is treated surgically. This outstanding difference in management challenges the longstanding approach that preoperative biopsies are not mandatory prior to nephrectomy for renal masses. Because of its relative rarity, the imaging features of PRL have been described in a few studies, and having an understanding of these typical imaging patterns is crucial for making an accurate diagnosis and differentiation from other renal malignancies. Here, we present a case of a secondary renal lymphoma and discuss its differential imaging features.

Identifiers

PMID37265750
PMCPMC10230230
OpenAlexW4362595804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.